肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

2022 ESMO专家共识声明：非小细胞肺癌EGFR突变的管理

2022-02-14 欧洲肿瘤内科学会 Ann Oncol

非小细胞肺癌肺癌

2022年2月，欧洲肿瘤内科学会(ESMO)发布了非小细胞肺癌EGFR突变的管理专家共识声明。目的是针对当前ESMO临床实践指南中为详细涵盖的主题以及可用证据有限或相互冲突的主题提出指导建议。

中文标题：

2022 ESMO专家共识声明：非小细胞肺癌EGFR突变的管理

英文标题：

ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer

发布机构：

欧洲肿瘤内科学会

发布日期：

2022-02-14

简要介绍：

2022年2月，欧洲肿瘤内科学会(ESMO)发布了非小细胞肺癌EGFR突变的管理专家共识声明。目的是针对当前ESMO临床实践指南中为详细涵盖的主题以及可用证据有限或相互冲突的主题提出指导建议，涉及组织和生物标志物分析、早期和局部晚期疾病、转移性疾病、临床试验设计等。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2022 ESMO专家共识声明：非小细胞肺癌EGFR突变的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=9d1571c002359e1b, title=2022 ESMO专家共识声明：非小细胞肺癌EGFR突变的管理, enTitle=ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer, guiderFrom=Ann Oncol, authorId=0, author=, summary=2022年2月，欧洲肿瘤内科学会(ESMO)发布了非小细胞肺癌EGFR突变的管理专家共识声明。目的是针对当前ESMO临床实践指南中为详细涵盖的主题以及可用证据有限或相互冲突的主题提出指导建议。, cover=https://img.medsci.cn/2022219/1645200778048_1608702.png, journalId=0, articlesId=null, associationId=14, associationName=欧洲肿瘤内科学会, associationIntro=欧洲肿瘤内科学会（ESMO，European Society for Medical Oncology )是1975年成立的非盈利组织，是欧洲领先的专业组织，致力于提高肿瘤内科的专业性，推进癌症治疗和护理的多学科诊疗方法。, copyright=0, guiderPublishedTime=Mon Feb 14 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2022年2月，欧洲肿瘤内科学会(ESMO)发布了非小细胞肺癌EGFR突变的管理专家共识声明。目的是针对当前ESMO临床实践指南中为详细涵盖的主题以及可用证据有限或相互冲突的主题提出指导建议，涉及组织和生物标志物分析、早期和局部晚期疾病、转移性疾病、临床试验设计等。</span></p>, tagList=[TagDto(tagId=276, tagName=非小细胞肺癌), TagDto(tagId=428, tagName=肺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5703, appHits=163, showAppHits=0, pcHits=810, showPcHits=5532, likes=1, shares=27, comments=9, approvalStatus=1, publishedTime=Sat Feb 19 15:10:00 CST 2022, publishedTimeString=2022-02-14, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Sat Feb 19 00:15:39 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 19:36:50 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 ESMO专家共识声明：非小细胞肺癌EGFR突变的管理.pdf)])
2022 ESMO专家共识声明：非小细胞肺癌EGFR突变的管理.pdf
下载请点击：
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1218775, encodeId=1bc91218e75bc, content=谢谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=315e2248623, createdName=1215d40cm36暂无昵称, createdTime=Wed May 11 16:28:00 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216159, encodeId=c320121615994, content=感谢 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJQk243lMkwqhPZdJAN8XicTRSkPNLE6Swviaut1HKYe9rf5MUATic1N2HDgf0c0ogDSN5xKS0iaDtyUA/132, createdBy=4e7f2238749, createdName=DOC.李红伟, createdTime=Sun May 01 21:36:28 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216158, encodeId=a956121615879, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJQk243lMkwqhPZdJAN8XicTRSkPNLE6Swviaut1HKYe9rf5MUATic1N2HDgf0c0ogDSN5xKS0iaDtyUA/132, createdBy=4e7f2238749, createdName=DOC.李红伟, createdTime=Sun May 01 21:34:59 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202897, encodeId=7bc9120289e72, content=已下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlsERBcznAdmbubHPOibYH38pqw4YpCd4tefxiclGCPVJQFvCg1VkIicDKjsiaJk1Z5ibcJyjgdIPc5lQ/132, createdBy=edf84781010, createdName=834882315, createdTime=Tue Mar 15 21:35:57 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202894, encodeId=c076120289497, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlsERBcznAdmbubHPOibYH38pqw4YpCd4tefxiclGCPVJQFvCg1VkIicDKjsiaJk1Z5ibcJyjgdIPc5lQ/132, createdBy=edf84781010, createdName=834882315, createdTime=Tue Mar 15 21:25:49 CST 2022, time=2022-03-15, status=1, ipAttribution=)]
    2022-05-11 1215d40cm36暂无昵称

    谢谢！

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1218775, encodeId=1bc91218e75bc, content=谢谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=315e2248623, createdName=1215d40cm36暂无昵称, createdTime=Wed May 11 16:28:00 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216159, encodeId=c320121615994, content=感谢 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJQk243lMkwqhPZdJAN8XicTRSkPNLE6Swviaut1HKYe9rf5MUATic1N2HDgf0c0ogDSN5xKS0iaDtyUA/132, createdBy=4e7f2238749, createdName=DOC.李红伟, createdTime=Sun May 01 21:36:28 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216158, encodeId=a956121615879, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJQk243lMkwqhPZdJAN8XicTRSkPNLE6Swviaut1HKYe9rf5MUATic1N2HDgf0c0ogDSN5xKS0iaDtyUA/132, createdBy=4e7f2238749, createdName=DOC.李红伟, createdTime=Sun May 01 21:34:59 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202897, encodeId=7bc9120289e72, content=已下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlsERBcznAdmbubHPOibYH38pqw4YpCd4tefxiclGCPVJQFvCg1VkIicDKjsiaJk1Z5ibcJyjgdIPc5lQ/132, createdBy=edf84781010, createdName=834882315, createdTime=Tue Mar 15 21:35:57 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202894, encodeId=c076120289497, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlsERBcznAdmbubHPOibYH38pqw4YpCd4tefxiclGCPVJQFvCg1VkIicDKjsiaJk1Z5ibcJyjgdIPc5lQ/132, createdBy=edf84781010, createdName=834882315, createdTime=Tue Mar 15 21:25:49 CST 2022, time=2022-03-15, status=1, ipAttribution=)]
    2022-05-01 DOC.李红伟

    感谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1218775, encodeId=1bc91218e75bc, content=谢谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=315e2248623, createdName=1215d40cm36暂无昵称, createdTime=Wed May 11 16:28:00 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216159, encodeId=c320121615994, content=感谢 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJQk243lMkwqhPZdJAN8XicTRSkPNLE6Swviaut1HKYe9rf5MUATic1N2HDgf0c0ogDSN5xKS0iaDtyUA/132, createdBy=4e7f2238749, createdName=DOC.李红伟, createdTime=Sun May 01 21:36:28 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216158, encodeId=a956121615879, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJQk243lMkwqhPZdJAN8XicTRSkPNLE6Swviaut1HKYe9rf5MUATic1N2HDgf0c0ogDSN5xKS0iaDtyUA/132, createdBy=4e7f2238749, createdName=DOC.李红伟, createdTime=Sun May 01 21:34:59 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202897, encodeId=7bc9120289e72, content=已下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlsERBcznAdmbubHPOibYH38pqw4YpCd4tefxiclGCPVJQFvCg1VkIicDKjsiaJk1Z5ibcJyjgdIPc5lQ/132, createdBy=edf84781010, createdName=834882315, createdTime=Tue Mar 15 21:35:57 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202894, encodeId=c076120289497, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlsERBcznAdmbubHPOibYH38pqw4YpCd4tefxiclGCPVJQFvCg1VkIicDKjsiaJk1Z5ibcJyjgdIPc5lQ/132, createdBy=edf84781010, createdName=834882315, createdTime=Tue Mar 15 21:25:49 CST 2022, time=2022-03-15, status=1, ipAttribution=)]
    2022-05-01 DOC.李红伟

    感谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1218775, encodeId=1bc91218e75bc, content=谢谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=315e2248623, createdName=1215d40cm36暂无昵称, createdTime=Wed May 11 16:28:00 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216159, encodeId=c320121615994, content=感谢 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJQk243lMkwqhPZdJAN8XicTRSkPNLE6Swviaut1HKYe9rf5MUATic1N2HDgf0c0ogDSN5xKS0iaDtyUA/132, createdBy=4e7f2238749, createdName=DOC.李红伟, createdTime=Sun May 01 21:36:28 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216158, encodeId=a956121615879, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJQk243lMkwqhPZdJAN8XicTRSkPNLE6Swviaut1HKYe9rf5MUATic1N2HDgf0c0ogDSN5xKS0iaDtyUA/132, createdBy=4e7f2238749, createdName=DOC.李红伟, createdTime=Sun May 01 21:34:59 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202897, encodeId=7bc9120289e72, content=已下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlsERBcznAdmbubHPOibYH38pqw4YpCd4tefxiclGCPVJQFvCg1VkIicDKjsiaJk1Z5ibcJyjgdIPc5lQ/132, createdBy=edf84781010, createdName=834882315, createdTime=Tue Mar 15 21:35:57 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202894, encodeId=c076120289497, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlsERBcznAdmbubHPOibYH38pqw4YpCd4tefxiclGCPVJQFvCg1VkIicDKjsiaJk1Z5ibcJyjgdIPc5lQ/132, createdBy=edf84781010, createdName=834882315, createdTime=Tue Mar 15 21:25:49 CST 2022, time=2022-03-15, status=1, ipAttribution=)]
    2022-03-15 834882315

    已下载

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1218775, encodeId=1bc91218e75bc, content=谢谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=315e2248623, createdName=1215d40cm36暂无昵称, createdTime=Wed May 11 16:28:00 CST 2022, time=2022-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216159, encodeId=c320121615994, content=感谢 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJQk243lMkwqhPZdJAN8XicTRSkPNLE6Swviaut1HKYe9rf5MUATic1N2HDgf0c0ogDSN5xKS0iaDtyUA/132, createdBy=4e7f2238749, createdName=DOC.李红伟, createdTime=Sun May 01 21:36:28 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216158, encodeId=a956121615879, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJQk243lMkwqhPZdJAN8XicTRSkPNLE6Swviaut1HKYe9rf5MUATic1N2HDgf0c0ogDSN5xKS0iaDtyUA/132, createdBy=4e7f2238749, createdName=DOC.李红伟, createdTime=Sun May 01 21:34:59 CST 2022, time=2022-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202897, encodeId=7bc9120289e72, content=已下载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlsERBcznAdmbubHPOibYH38pqw4YpCd4tefxiclGCPVJQFvCg1VkIicDKjsiaJk1Z5ibcJyjgdIPc5lQ/132, createdBy=edf84781010, createdName=834882315, createdTime=Tue Mar 15 21:35:57 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202894, encodeId=c076120289497, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlsERBcznAdmbubHPOibYH38pqw4YpCd4tefxiclGCPVJQFvCg1VkIicDKjsiaJk1Z5ibcJyjgdIPc5lQ/132, createdBy=edf84781010, createdName=834882315, createdTime=Tue Mar 15 21:25:49 CST 2022, time=2022-03-15, status=1, ipAttribution=)]
    2022-03-15 834882315

    学习

    0

相关指南

《CSCO非小细胞肺癌诊疗指南2021》更新要点解读

国家癌症中心 · 2022-02-10

2022 非小细胞肺癌HER2改变检查共识

中国肿瘤科相关专家小组（统称） · 2022-02-08

2021 ESMO 临床实践指南的更新：早期和局部晚期非小细胞肺癌：侧重于诊断、分期、全身和局部治

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2021-09-01

中国非小细胞肺癌免疫检查点抑制剂治疗专家共识（2020年版）

国家癌症中心 · 2021-04-20

2021 加拿大共识建议：MET突变非小细胞肺癌的管理

加拿大安大略癌症治疗中心(CCO,Cancer Care Ontario) · 2021-11-09

2021专家共识：局部晚期非小细胞肺癌围术期免疫治疗

中国肿瘤科相关专家小组（统称） · 2021-09-10